{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-012701","form_type":"8-K","ticker":"TVGN","cik":"0001860871","company_name":"Tevogen Bio Holdings Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.591141+00:00","generated_at":"2026-05-15T09:04:10.424309+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tevogen Bio regains Nasdaq minimum bid price compliance after reverse split","bullets":["Received Nasdaq notice on March 20, 2026 confirming compliance with Listing Rule 5450(a)(1).","Compliance achieved via 1-for-50 reverse stock split of common stock effective March 6, 2026.","Nasdaq matter now closed; no further delisting risk from this requirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-012701","json":"https://secwatch.observer/filing/0001493152-26-012701.json","markdown":"https://secwatch.observer/filing/0001493152-26-012701.md","text":"https://secwatch.observer/filing/0001493152-26-012701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860871/000149315226012701/0001493152-26-012701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860871/000149315226012701/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:04:10.424309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}